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ABSTRACT
Aims: To evaluate the safety of up to 3 years of
pegaptanib sodium therapy in the treatment of neovas-
cular age-related macular degeneration (NV-AMD).
Methods: Two concurrent, prospective, multicentre,
double-masked studies randomised subjects with all
angiographic lesion compositions of NV-AMD to receive
intravitreous pegaptanib sodium (0.3, 1 and 3 mg) or
sham injections every 6 weeks for 54 weeks. Those
initially assigned to pegaptanib were rerandomised to
continue or discontinue therapy for 48 more weeks;
sham-treated subjects continued sham, discontinued or
received pegaptanib. At 102 weeks, subjects receiving
pegaptanib 0.3 mg or 1 mg in years 1 or 2 continued;
those receiving pegaptanib 3 mg or who did not receive
treatment in years 1 and 2 were rerandomised to 0.3 mg
or 1 mg for year 3.
Results: As in years 1 and 2, pegaptanib was well
tolerated in year 3. Adverse events were mainly ocular in
nature, mild, transient and injection-related. Serious
adverse events were rare. No evidence of systemic safety
signals attributed to vascular endothelial growth factor
inhibition arose in year 3. There were no findings in
relation to vital signs or electrocardiogram results
suggesting a relationship to pegaptanib treatment.
Conclusion: The 3-year safety profile of pegaptanib
sodium was favourable in patients with NV-AMD.
Vascular endothelial growth factor (VEGF) plays
important roles in a wide variety of physiological
processes, some reflecting its role in promoting
angiogenesis and others important for normal
physiological functions, such that issues of safety
are of particular concern for long-term therapies
premised on its inhibition. Physiological VEGF
expression is now known to be important for
protection of hepatocytes
1 and renal cells,
23 for
wound healing,
45 female reproductive cycling,
67
bone growth,
68trophic maintenance of capillaries
9
and neurons.
10 In the eye, VEGF plays a physio-
logical role in the development and trophic
maintenance of the choriocapillaris
11 12 and in
protecting retinal neurons from apoptosis in
conditions of ischaemia.
13 14 The systemic use of
bevacizumab (Avastin), a humanised antibody
blocking all VEGF isoforms, in cancer treatment
regimens has been accompanied by increased
incidences of systemic hypertension, bleeding,
proteinuria,gastrointestinalperforationsandthrom-
boembolic events.
15–17 While the intravitreous mode
of administration of anti-VEGF agents would be
expected to reduce the severity of these systemic
events, potential concerns remain, given the sys-
temic levels, observed response in the fellow eye
after intravitreous administration and the long-term
maintenance therapy that some patients may
require.
18 19
Preclinical findings in animal models have
suggested that the selective inhibition by intra-
vitreous pegaptanib, which targets VEGF165,a n
especially proinflammatory isoform,
20–22 and spares
VEGF120, could minimise some of the safety issues.
While providing clinical benefit in the treatment of
all angiographic subtypes of neovascular age-
related macular degeneration (NV-AMD),
23 24 con-
tinuous intravitreous pegaptanib sodium has been
shown to have an excellent safety profile over
2 years.
23 25 We now present further data for
patients who have continued for 3 years in the
VEGF Inhibition Study in Ocular
Neovascularisation (VISION) trial, showing that




The details of the design of the VISION trial have
been reported.
23 25 The study protocol was
reviewed and approved by an institutional review
board at each study site in accordance with the
guidelines for the conduct of clinical research in the
1964 Declaration of Helsinki. Study participants
provided signed informed consent before baseline
procedures were performed. In brief, two identi-
cally designed, phase 3, prospective, comparative
studies comprised the trial; both had randomised,
double-masked, controlled, dose-ranging, multi-
centre, parallel-group designs (fig 1). At baseline,
patients were randomised to one of four treatment
groups (0.3 mg, 1 mg or 3 mg of pegaptanib
sodium in 0.09 ml of solution or sham injections)
and received nine intravitreous or sham injections
once every 6 weeks for 48 weeks with follow-up to
week 54. At week 54, subjects in the active therapy
arms were rerandomised (1:1) to either discontinue
or continue treatment for a further 48 weeks (eight
injections). Subjects receiving sham were rerando-
mised at week 54 (1:1:1:1:1) to discontinue sham
treatment, to continue on the study receiving one
of the three active treatments or to continue on
sham therapy.
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the study eye of 20/800 or better continued treatment for a
further nine injections in the third year (week 102 to week 150
with follow-up to week 156). Those receiving the 0.3 mg or
1 mg dose in year 2 continued on the same treatment, while
subjects receiving the 3 mg dose or sham were rerandomised to
0.3 mg or 1 mg (1:1). Subjects not on treatment during the
second year but who had received 0.3 mg or 1 mg during the
Figure 1 Randomisation at years 1, 2
and 3.
Figure 2 (A) Mean blood pressure
through 3 years: subjects who received
0.3 mg of pegaptanib sodium for all
3 years, n=52. (B) Mean blood pressure
through 3 years: subjects who received
1 mg of pegaptanib sodium for all
3 years, n=57.
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on treatment during year 2 but who had received 3 mg or sham
during year 1 were rerandomised to receive 0.3 mg or 1 mg (1:1).
In year 3, study participants were masked to the actual dose
being administered but were aware that only active 0.3 mg and
1 mg doses were being administered.
Clinical monitoring
Throughout the study, safety was assessed by adverse event
reporting, ophthalmic examination, applanation tonometry,
laboratory assessments, electrocardiograms (ECGs) and vital
signs. Laboratory tests included haematology (complete blood
counts) and chemistry (electrolytes, renal and hepatic) assess-
ments. Adverse events were assessed by investigators for the
relationship to the injection procedure and to study the drug.
Independent data monitoring
An Independent Data Monitoring Committee consisting of
experts independent from the sponsors and the investigators
was established before the trial’s start. The committee reviewed
the data and procedures of both studies on an ongoing basis to
ensure subject safety.
End points and analyses
Safety end-points included all adverse events and serious
adverse events (ophthalmic or systemic), intraocular pressure
(IOP), clinical laboratory data, ECG abnormalities and changes,
and loss of .20 letters (four lines; Early Treatment of Diabetic
Retinopathy Study) of visual acuity between visits. Adverse
events were coded according to the Medical Dictionary for
Regulatory Activities 5.1. If the subject experienced more than
one occurrence of the same event, only the event with the
highest severity value was counted.
Safety data were tabulated for the combined population of
the two studies, and year 3 adverse events were those with an
onset date from week 102 (including the injection day at week
102) up to week 156 (excluding the injection day at week 156).
Unless otherwise specified, the safety population included all
subjects who received active pegaptanib sodium therapy at any
dose throughout years 1, 2 and 3. Analyses of injection-related
serious adverse events included all subjects who received
pegaptanib sodium in year 3 regardless of previous randomised
treatment (ie, sham or treatment discontinued). Assessments of
IOP changes were performed in subjects who received 0.3 mg or
1 mg of pegaptanib sodium continuously from years 1 to 3.
Statistical analyses on year 3 data were limited by small sample
sizes and were considered to be descriptive.
RESULTS
In all, 165 subjects who received active therapy with pegaptanib
sodium in the first 2 years of the study were rerandomised at
week 102. The rerandomised population was predominantly
white with a higher ratio of females to males and a mean age in
the mid-70s. Patient groups generally were similar to those
reported at 54 and 102 weeks.
23–25 The primary safety popula-
tion consisted of the 161 subjects who received at least one dose
of study medication in year 3 (75 received 0.3 mg, and 86
received 1 mg; four patients were randomised but did not
receive study medication) and who received active treatment
throughout years 1 and 2. The total number of injections
administered in these 161 subjects during year 3 was 1254
(mean injections per patient=7.8). In all, 422 subjects received
a total of 3227 injections of pegaptanib sodium 0.3 mg or 1 mg
in year 3 regardless of treatment in previous years.
As seen in years 1 and 2, pegaptanib sodium was well
tolerated in year 3, and adverse events were mainly ocular in
nature, mild and predictable. Ocular adverse events occurred in
114/161 (71%) subjects in the primary safety population in year
3, and the majority of events were associated with the injection
procedure (table 1). Twenty-seven (17%) subjects experienced
serious ocular or non-ocular adverse events, and 3% discon-
tinued due to an adverse event.
Ocular adverse events reported in study eyes in >5% of the
primary safety population subjects are summarised in table 2.
The most common ocular adverse events were punctate
keratitis (41/161 (25%)), increased IOP (32/161 (20%)), eye
pain (27/161 (17%)), and cataract (23/161 (14%)). The incidence
of these events was similar to or less than the incidence in years
1 and 2 of the study. As in previous years, no severe anterior
chamber inflammation was seen, and the assessment of cataract
in phakic subjects did not suggest that pegaptanib sodium
injections were associated with cataract progression. During the
third year, 8/161 (5%) subjects lost 20 or more letters of vision,
and five of these fully or partially improved in subsequent visits.
Injection-related serious adverse events were rare in the 422
subjects treated with pegaptanib sodium 0.3 mg or 1 mg in year
3, regardless of treatment in previous years (table 3). Two cases
of endophthalmitis (0.06% per injection, 0.47% per patient), one
case of rhegmatogenous retinal detachment (0.03% per injec-
tion, 0.24% per patient) and no cases of traumatic cataract were
reported. One case of vitreous haemorrhage was reported as a
serious ocular adverse event and was assessed by the investi-
gator to be related to the injection procedure. One reported
event of reduced visual acuity of at least four lines between two
Table 1 Adverse event summary, study eye (year 3
safety population) (n (%))
All subjects who
received active
therapy for 3 years
n=161
Subjects with any adverse event 142 (88)
Subjects with an ocular adverse event 114 (71)
Injection-procedure related 84 (52)
Study-therapy related 19 (12)
Subjects with any serious adverse event 27 (17)
Subjects discontinuing due to an adverse event 5 (3)
Table 2 Adverse events reported in study eyes in >5%
of subjects (year 3, safety population) (n (%))
Adverse event
All subjects who received
active therapy for 3 years
n=161
Punctate keratitis 41 (25)
Intraocular pressure increased 32 (20)
Eye pain 27 (17)
Cataract 23 (14)
Vitreous floaters 18 (11)
Conjunctival haemorrhage 15 (9)
Anterior chamber inflammation 14 (9)
Corneal oedema 13 (8)
Vitreous opacities 13 (8)
Visual acuity reduced 10 (6)
Eye pruritus 8 (5)
Lacrimation increased 8 (5)
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experienced endophthalmitis) was assessed to be related to the
injection procedure. In addition, one subject experienced retinal
haemorrhage and vitreous haemorrhage that were assessed to be
related to the study drug, but not reported as a serious ocular
adverse event.
The general pattern of IOP changes seen in years 1 and 2
continued in year 3. On average, subjects experienced an
increase in IOP at the 30 min postinjection assessment
compared with preinjection at each treatment visit. At the 1-
week postinjection assessment, the pressure had returned to
levels similar to preinjection. Of subjects treated with 0.3 mg or
1 mg of pegaptanib sodium continuously for 3 years, the mean
IOP remained stable throughout the 3 years, and more than
80% of subjects did not experience IOP values >35 mm Hg at
any time. Intervention for increased IOP on injection days
also was relatively infrequent. Ten of 109 (9%) underwent
paracenteses, and only 17 (16%) required treatment with
concomitant medications for increased IOP on one or more
injection days during the 3-year follow-up.
The Independent Reading Center graded all baseline and
week 30, 54, 78, 102 and 156 fluorescein angiograms. These
examinations revealed no retinal vascular abnormalities that are
unexpected in the natural history of NV-AMD. Specifically,
there were no notable delays in arteriovenous transit time, or
abnormalities in choroidal perfusion or arteriolar occlusions.
As in years 1 and 2, no evidence of systemic safety signals
related to the inhibition of VEGF arose with the third year of
administration of pegaptanib sodium. In the 161 subjects
receiving active therapy for 3 years, the most common
nonocular adverse events in year 3 were infections and
infestations (18%); respiratory, thoracic and mediastinal dis-
orders (15%); and gastrointestinal disorders (14%) (table 4).
There were no thromboembolic cerebrovascular accidents; only
two subjects had an event of myocardial infarction (2%), and
one subject had an event of angina (1%). The incidence of these
thromboembolic events was the same among the entire cohort
of 422 subjects treated with pegaptanib sodium in year 3 and
was similar to those observed in the pegaptanib and sham
groups in years 1 and 2. There were no serious nonocular
haemorrhagic events. Among the entire cohort of 422 subjects
treated with pegaptanib sodium in year 3, the most frequently
occurring serious adverse events were neoplasms and cardiac
disorders, each experienced by 12 subjects (3%); gastrointestinal
disorders (10 subjects, 2%); and vascular disorders (nine
subjects, 2%). With the exception of one event of hypertension
that the investigator assessed to be related to the injection
procedure (the event occurred before an injection, and the
investigator considered that the event was due to the subject’s
emotions in connection with the subsequent injection), none of
these events was related to the injection procedure or the study
drug. There were six deaths (1%) among the 422 subjects who
received pegaptanib sodium in year 3; none of the deaths was
considered to be related to study drug or injection procedure by
the investigator. The adverse events associated with these death
cases were glioblastoma, cardiac arrest, Clostridium colitis,
cardiorespiratory arrest, hypotension and metastatic lung
cancer, one case each.
There were no findings in relation to vital signs performed at
each clinical assessment or ECG test results that were suggestive
of a relationship to treatment with pegaptanib sodium; in
particular, there was no evidence of an increase in mean blood
pressure over the 3 years of treatment (fig 2). There were no
laboratory test findings suggestive of a relationship with
pegaptanib sodium. Specifically, when the median change from
baseline was reviewed for the laboratory parameters, there was
no evidence of a clinically meaningful pattern. Additionally,
analysis of clinically significant laboratory abnormalities for
individual patients revealed the majority to be transient, with
no findings to suggest a relationship between treatment with
pegaptanib sodium and these abnormalities.
DISCUSSION
The data from the VISION trial demonstrate a favourable
ocular and systemic safety profile for 3 years of continuous
selective VEGF inhibition with pegaptanib sodium for the
treatment of NV-AMD. No new safety signals emerged during
the third year of therapy with pegaptanib sodium. Subjects’
compliance with intravitreal injections of pegaptanib sodium
during the third year also was consistent with the previous
2 years of the study.
There was no change in the ocular safety profile of
pegaptanib sodium in the third year. In year 3, as in the
previous years, adverse events were mainly ocular in nature,
mild, transient and related to the injection procedure. The
incidence of the most commonly reported ophthalmic adverse
events (eg, punctate keratitis, eye pain, vitreous floaters and
cataract) decreased during the second
25 and third years of the
studies. While there was no sham group in the third year of the
study, the most common ocular events in years 1 and 2 were
reported in a higher proportion of study eyes of sham patients
relative to the fellow eyes of each active treatment group,
Table 3 Serious ocular adverse events reported in study




sodium 0.3 mg or 1 mg
in year 3 n=422 (no of
injections=3227)
Endophthalmitis 2 (0.06% per injection)
Rhegmatogenous retinal detachment 1 (0.03% per injection)
Traumatic cataract 0 (0.0% per injection)
Vitreous haemorrhage 1 (0.03% per injection)
Table 4 All-causality non-ocular adverse events in >5%
of subjects (year 3, safety population) (n (%))







Infections and infestations 29 (18)
Respiratory, thoracic and mediastinal disorders 24 (15)
Gastrointestinal disorders 23 (14)
Musculoskeletal and connective tissue disorders 20 (12)
Nervous system disorders 18 (11)
Cardiac disorders 17 (11)
Injury, poisoning and procedural complications 16 (10)
Vascular disorders 15 (9)
Skin and subcutaneous tissue disorders 14 (9)
Metabolism and nutrition disorders 10 (6)
Neoplasms benign, malignant and unspecified 9 (6)
*The majority of these events were ‘‘increased intraocular pressure
(IOP)’’; the investigators were required to report an IOP of >30 mm
Hg at 30 min after injection as an adverse event.
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preparation procedure for the intravitreous injection rather than
to the intravitreous injection itself. There was no case of severe
anterior chamber inflammation, which suggests that no
significant intraocular activation of the immunological response
was triggered. This was consistent with previous studies that
employed an aptamer for therapy
26 and with those demonstrat-
ing an absence of detectable serum antibodies against pegapta-
nib.
27 Although extremely rare cases of anaphylactoid reactions
have been reported in patients receiving pegaptanib (Macugen
(package insert). New York: (OSI) Eyetech; 2006), it is not clear
if the response is triggered by pegaptanib or some other
component of the preparation or procedure. Additionally, there
was no evidence of a difference in cataract progression between
the third year and previous years. No unexpected changes in the
choroidal and retinal vasculatures were seen even after 3 years
of selective VEGF inhibition.
The low rate of serious ocular events continued during study
year 3, with the incidence of rhegmatogenous retinal detach-
ment only 0.03% per injection (1/3227), and no iatrogenic
traumatic cataracts were reported. The rate of endophthalmitis
continued to decline over the course of the studies from 0.16%
per injection (12 of 7545 injections) in the first year to 0.10% per
injection (4/4091) in the second year
25 and to 0.06% per
injection (2/3227) in the third year (p,0.0001, Cochran–
Armitage trend test). This decrease in the rate of endophthal-
mitis may result at least partially from a protocol amendment
emphasising the importance of adherence to aseptic technique
when performing intravitreal injections. The lower rate of
endophthalmitis also may be attributed to the widespread
adoption of and increasing familiarity with intravitreous
injections by retina specialists over the 3 years of this study.
There was also no change in the systemic safety profile of
pegaptanib sodium. The types and incidence of systemic serious
adverse events observed are not unexpected in this elderly
patient population, and none of these events was judged to be
related to study drug. This favourable systemic safety profile is
of particular importance for the NV-AMD population that is at
higher risk for cardiovascular and thromboembolic diseases.
28 In
conclusion, 3 years of continuous selective VEGF inhibition
with pegaptanib sodium in the treatment of patients with NV-
AMD confirmed the favourable safety profile of pegaptanib
sodium.
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